Track market-moving stories before they get noisy

Defense Earnings Show Readiness Now and Modernization AheadRyder System NYSE: R reported its seventh consecutive quarter of comparable earnings-per-share growth, with management pointing to contractual revenue, strategic initiatives and improving used vehicle sales as the main contributors to second-quarter 2026 results.

Chief Executive Officer John Diez said Ryder’s “transformed model” continued to outperform prior cycles, supported by a shift toward less capital-intensive businesses and long-term customer contracts. He said more than 90% of Ryder’s revenue is generated through long-term contracts, which management views as a key factor in the company’s resilience during the freight cycle.

Get Ryder System alerts:

Prepare for the Next Wave of Factory Automation With These 3 Standout Names“The Ryder team delivered our seventh consecutive quarter of comparable EPS growth,” Diez said. “Solid results were primarily driven by consistent execution on our strategic initiatives. Improving market conditions and used vehicle sales also contributed to our higher results.”

For the quarter, Ryder posted total operating revenue of $2.7 billion, up 3% from the prior year. Comparable earnings per share from continuing operations were $3.73, up 12% year over year. Return on equity was 17%, in line with the prior year. Free cash flow rose to $684 million from $461 million, which Executive Vice President and Chief Financial Officer Cristy Gallo-Aquino attributed to lower capital expenditures.

Fleet Management Leads Earnings Growth CEOs Sell Millions Worth of These 3 Big Name Stocks—What It Means for InvestorsFleet Management Solutions was the primary driver of higher earnings in the quarter. The segment’s operating revenue increased, reflecting contractual revenue growth, partially offset by lower rental demand. Earnings before taxes rose 20% from the prior year to $150 million.

Gallo-Aquino said the improvement reflected benefits from strategic initiatives in the ChoiceLease business, along with strengthening used vehicle market conditions. Fleet Management EBT as a percentage of operating revenue was 11.5%, up from a year earlier but still below Ryder’s long-term target of the low teens over the cycle.

Rental utilization returned to Ryder’s targeted level of 75% on a 15% smaller average fleet. Gallo-Aquino said demand remained below the prior year and historical seasonal trends, but the quarter represented the strongest sequential increase in four years. Rental pricing increased 1% from the prior year.

Used vehicle sales showed improvement as well. Year-over-year used tractor pricing increased 3%, while truck pricing rose 6%. Sequentially, overall pricing was stable, but retail pricing improved 7% for trucks and 3% for tractors. Ryder sold 5,100 used vehicles in the quarter, up 500 units sequentially but down 1,100 units from a year earlier, largely reflecting elevated wholesaling activity in the prior year. Used vehicle inventory declined to 8,500 vehicles, within Ryder’s target range.

Supply Chain and Dedicated Results Mixed Supply Chain Solutions operating revenue increased 7%, driven by new business, partially offset by lost business in automotive. Segment earnings before taxes declined 7% year over year, which Ryder attributed to lower automotive results and, to a lesser extent, productivity issues tied to new business ramp-ups. Benefits from optimization of the company’s omni-channel retail network partially offset those pressures.

Supply Chain EBT as a percentage of operating revenue was 8.4%, which management said was at the segment’s long-term high-single-digit target. Gallo-Aquino noted that comparisons were challenging because the prior-year quarter included record results.

Dedicated Transportation Solutions operating revenue declined 3% due to a lower fleet count, partially offset by higher pricing. Earnings before taxes were lower than a year ago, reflecting reduced operating revenue and adverse development of prior-year insurance claims, partly offset by strategic initiative benefits. Dedicated EBT as a percentage of operating revenue was 7.9%, also at the segment’s long-term high-single-digit target.

Guidance Raised on Used Vehicle Outlook Ryder raised the low end of its full-year 2026 comparable EPS forecast to $14.40 from $14.05, while keeping the high end at $14.80. Diez said the increase largely reflected an improved outlook and reduced downside in used vehicle sales. Ryder now expects used vehicle sales gains of about $40 million for the full year, up $10 million from its prior forecast.

That benefit is expected to be partially offset by the timing of new business onboarding in Supply Chain. Ryder also revised its 2026 return on equity forecast to 18%, compared with its prior range of 17% to 18%. The company maintained its free cash flow forecast of $700 million to $800 million. For the third quarter, Ryder forecast comparable EPS of $4.00 to $4.20, above the prior-year result of $3.57.

Diez said Ryder remains on track to deliver $70 million in incremental benefits from strategic initiatives in 2026. Those initiatives are part of a $170 million multi-year program launched in 2024 and include lease pricing, maintenance cost savings, Dedicated margin improvement actions and Supply Chain network optimization.

Management also said Ryder could benefit meaningfully from a freight cycle upturn. By the next cycle peak, Ryder estimates a potential $250 million benefit, primarily from rental and used vehicle sales recovery in Fleet Management, with additional benefits from higher omni-channel retail volumes.

Capital Spending and Shareholder Returns Year-to-date lease capital spending was $605 million, below the prior year due to timing of replacement activity. Ryder expects full-year 2026 lease spending of $1.9 billion and rental spending of $200 million. Total capital expenditures are forecast at approximately $2.4 billion, with net capital expenditures expected to be about $1.9 billion after roughly $500 million in proceeds from used vehicle sales.

Gallo-Aquino said Ryder’s contractual base is generating higher earnings and cash flow, helping reduce leverage and create additional debt capacity. Over a three-year period, Ryder expects to generate about $10.5 billion from operating cash flow and used vehicle sales proceeds, creating approximately $14 billion available for capital deployment when incremental debt capacity is included.

The company estimates that about $9.5 billion will be used for lease and rental replacement vehicles and dividends, leaving around $4.5 billion for flexible deployment to support growth, acquisitions, investments and share repurchases. Ryder returned $406 million to shareholders through buybacks and dividends year to date. The board also authorized a new discretionary 2 million share repurchase program and approved an 11% increase to the quarterly dividend, marking the fourth consecutive year of a double-digit dividend increase.

Management Sees Strong Sales Pipelines During the question-and-answer session, management said sales activity remained strong across the business. Diez said Fleet Management had seen two consecutive quarters of positive net sales, with fleet growth expected to improve toward the end of 2026 and into 2027. Tom Havens, President of Fleet Management Solutions, said the lag between sales and fleet additions reflects the time required to order and place vehicles into service.

In Dedicated, Diez said record pipelines reflected customer interest in outsourced capacity as the trucking market tightens. He cited rising costs, tighter driver capacity and higher insurance costs as trends supporting the Dedicated business.

Analysts also asked about competition in Supply Chain, including Amazon’s logistics offerings. Diez said Ryder had not seen an impact on its sales pipeline. Steve Sensing, President of Supply Chain Solutions and Dedicated Transportation Solutions, said Ryder had not yet encountered Amazon in requests for quotes and emphasized that Ryder’s Supply Chain solutions are typically customized, dedicated operations for individual customers.

Diez said freight market conditions are improving, but remain below normalized levels, with geopolitical and macroeconomic factors still affecting the pace and durability of recovery.

About Ryder System (NYSE:R)Ryder System, Inc is a leading provider of transportation and supply chain management solutions, serving commercial customers across a range of industries. The company's Fleet Management Solutions segment offers full-service leasing and rental of medium- and heavy-duty trucks, tractors and trailers, along with maintenance and repair services at its network of service locations. Its Supply Chain Solutions segment provides integrated, technology-driven offerings that span managed transportation, dedicated contract carriage, warehousing and distribution, and e-commerce fulfillment.

Founded in 1933 and headquartered in Miami, Florida, Ryder has grown from a regional truck leasing operation into a diversified, global logistics provider.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Ryder System Right Now?Before you consider Ryder System, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ryder System wasn't on the list.

While Ryder System currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Ryder System, Inc. (R) Q2 2026 Earnings Call July 23, 2026 11:00 AM EDT

Company Participants

Calene Candela - Vice President of Investor Relations
John Diez - CEO & Director
Cristina Gallo-Aquino - CFO, EVP & Principal Accounting Officer
John Sensing - President of Global Supply Chain Solutions & Dedicated Transportation Solutions
Tom Havens - President of Global Fleet Management Solutions

Conference Call Participants

Bascome Majors - Stephens Inc., Research Division
Jordan Alliger - Goldman Sachs Group, Inc., Research Division
Robert Salmon - Wells Fargo Securities, LLC, Research Division
Nancy Hipp - Morgan Stanley, Research Division
Harrison Bauer - Susquehanna Financial Group, LLLP, Research Division
Brandon Oglenski - Barclays Bank PLC, Research Division
Jeffrey Kauffman - Citizens JMP Securities, LLC, Research Division
Scott Group - Wolfe Research, LLC
Benjamin Mohr Mok - Citigroup Inc., Research Division
Brian Ossenbeck - JPMorgan Chase & Co, Research Division

Presentation

Operator

Good morning, and welcome to the Ryder System Second Quarter 2026 Earnings Release Conference Call. [Operator Instructions] Today's call is being recorded. If you have any objections, please disconnect at this time. I would now like to introduce Ms. Calene Candela, Vice President, Investor Relations for Ryder. Ms. Candela, you may begin.

Calene Candela
Vice President of Investor Relations

Thank you. Good morning, and welcome to Ryder's Second Quarter 2026 Earnings Conference Call. I'd like to remind you that during this presentation, you'll hear some forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from these expectations due to changes in economic, business, competitive, market, political and regulatory factors.

More detailed information about these factors and a reconciliation of each non-GAAP financial measure to the nearest GAAP measure is contained in this morning's earnings release, earnings call presentation

Ryder (R - Free Report) came out with quarterly earnings of $3.73 per share, beating the Zacks Consensus Estimate of $3.7 per share. This compares to earnings of $3.32 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +0.81%. A quarter ago, it was expected that this truck leasing company would post earnings of $2.29 per share when it actually produced earnings of $2.54, delivering a surprise of +10.92%.

Over the last four quarters, the company has surpassed consensus EPS estimates three times.

Ryder, which belongs to the Zacks Transportation - Equipment and Leasing industry, posted revenues of $3.35 billion for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 1.14%. This compares to year-ago revenues of $3.19 billion. The company has topped consensus revenue estimates just once over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Ryder shares have added about 44.4% since the beginning of the year versus the S&P 500's gain of 9.6%.

What's Next for Ryder?While Ryder has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Ryder was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $4.23 on $3.36 billion in revenues for the coming quarter and $14.73 on $13.22 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Transportation - Equipment and Leasing is currently in the bottom 31% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Another stock from the same industry, Freightcar America (RAIL - Free Report) , has yet to report results for the quarter ended June 2026.

This rail car maker is expected to post quarterly earnings of $0.01 per share in its upcoming report, which represents a year-over-year change of -90.9%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Freightcar America's revenues are expected to be $109.92 million, down 7.3% from the year-ago quarter.

Ryder System, Inc. (NYSE: R) reported results for the three months ended June 30 as follows: This press release features multimedia. View the full release her

MIAMI--(BUSINESS WIRE)--Ryder System, Inc. (NYSE: R) is expanding its used vehicle sales program with the launch of the Ryder Vehicle Assurance Program, a new offering designed to give buyers greater confidence when purchasing pre-owned commercial vehicles. Through the end of the year, Ryder is introducing a free 60‑day limited warranty on all Ryder DOT Verified vehicles. The promotional offering strengthens Ryder's position in the commercial vehicle market and provides buyers with added protec.

Ryder (R - Free Report) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.

The earnings report, which is expected to be released on July 23, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.

While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.

Zacks Consensus EstimateThis truck leasing company is expected to post quarterly earnings of $3.71 per share in its upcoming report, which represents a year-over-year change of +11.8%.

Revenues are expected to be $3.28 billion, up 2.9% from the year-ago quarter.

Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 1.05% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.

Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.

Price, Consensus and EPS Surprise

Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.

A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.

Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).

How Have the Numbers Shaped Up for Ryder?For Ryder, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -0.41%.

On the other hand, the stock currently carries a Zacks Rank of #2.

So, this combination makes it difficult to conclusively predict that Ryder will beat the consensus EPS estimate.

Does Earnings Surprise History Hold Any Clue?Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.

For the last reported quarter, it was expected that Ryder would post earnings of $2.29 per share when it actually produced earnings of $2.54, delivering a surprise of +10.92%.

Over the last four quarters, the company has beaten consensus EPS estimates three times.

Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.

That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

Ryder doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.

BioLargo's newly formed subsidiary, BioLargo CPG, will bring to consumers the authentic, independently safety-tested CupriDyne® technology under its own brand following the marketing success of the original Pooph products that generated more than $125 million in pet-care sales while under license from BioLargo.

WESTMINSTER, CA / ACCESS Newswire / July 13, 2026 / BioLargo, Inc. (OTCQX:BLGO) today announced that it is preparing to relaunch CupriDyne®-based consumer pet products under a yet-to-be-announced brand. Targeting pets first, the new consumer products subsidiary will eventually expand into household odor and cleaning products. Formed to fill the gap left by Pooph's ongoing withdrawal from the market, BioLargo will sell direct to consumers and through online marketplaces such as Amazon, leveraging a "digital-first" strategy that allows for hyper-specific audience targeting, real-time performance tracking, and flexible budgets, rather than depending on expensive television campaigns.

CupriDyne-based pet products generated over $125 million in sales while under license and marketed under the Pooph brand. Unfortunately, a series of business decisions by Pooph's management later culminated in its abandonment of CupriDyne-formulated products, the foreclosure of their assets by their lender, board and CEO resignations, and what appears to be the cessation of business operations. BioLargo always owned the CupriDyne technology and had to revoke Pooph's license. Now, the ownership of the Pooph brand is embroiled in litigation. "As a result, we have an opportunity to leverage the prior marketing success by introducing our own brand" said Joseph Provenzano, who will lead the new BioLargo consumer products subsidiary as CEO.

BioLargo's launch brings the CupriDyne® technology and BioLargo's original products back to consumers who loved them. According to Grand View Research1, the U.S. pet odor control and clean-up products market was valued at approximately $6.47 billion in 2023 and is projected to reach approximately $8.87 billion by 2030. BioLargo's initial launch into pet odor control is part of a much larger home and pet cleaning opportunity. The company views pet care as a proven, well-defined category where the difference between masking and eliminating odors is immediately obvious to consumers. Unlike the Pooph brand, BioLargo's new brand will not be limited to pets, and will use the pet product launch to anchor a broader expansion of CupriDyne products across the home.

BioLargo has assembled a team of branding, marketing, creative, and channel-sales experts with proven track records building and growing consumer brands nationally in the pet and household categories. It plans to release additional information, including the product line, the brand name, and key team members, as the product nears its formal launch.

"It will be great to get back into the pet odor control and consumer products business", said Dennis Calvert, BioLargo CEO. "We have seen what can be done, and this time we will own the brand and control the marketing and distribution."

About BioLargo, Inc.

BioLargo, Inc. (OTCQX:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com.

CONTACT:

Investor Relations
Matt Kreps
Darrow Associates, Inc.
214-597-8200
[email protected]

Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863
[email protected]

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo's (the "Company") expectations regarding anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of regional economic conditions on the Company's business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company's products. More information on these risks and other potential factors that could affect the Company's business and financial results is included in the Company's filings with the SEC, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

1 Grand View Research (2004), U.S. Pet Odor Control & Clean-up Products Market(2024 - 2030) https://www.grandviewresearch.com/industry-analysis/us-pet-odor-control-clean-up-products-market-report

SOURCE: BioLargo, Inc

MIAMI--(BUSINESS WIRE)-- #RyderEverbetter--Ryder increases quarterly cash dividend and marks 50 years of uninterrupted payments.

Brisbane, Queensland, Australia--(Newsfile Corp. - July 9, 2026) - Graphene Manufacturing Group Ltd. (TSXV: GMG) (OTCQX: GMGMF) ("GMG" or the "Company") is pleased to announce positive performance test results for its THERMAL XR® ENHANCE coating - now surpassing 30,000 hours of salt spray testing under test method ASTM B117-19 at an external laboratory.

Figure 1 shows the certification of no corrosion after 30,000 hours of salt spray testing from an external laboratory in the USA.

Figure 1: Certification of 30,000 hours of salt spray test ASTM B117-19 for THERMAL-XR®

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/8082/304571_b07b8c7464006bc2_001full.jpg

Figure 2 shows the images of the THERMAL-XR® coated plates upon the commencement of tests. Figure 3 shows the images of the various THERMAL-XR® coated plates after 30,000 hours of salt spray testing.

Figure 2: Image of THERMAL-XR® coated plates upon commencement of tests

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/8082/304571_b07b8c7464006bc2_002full.jpg

Figure 3: Images of THERMAL-XR® coated plates after 30,000 hours of salt sea spray testing

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/8082/304571_gmg3en.jpg

GMG's Managing Director and CEO, Craig Nicol, commented: "Reaching more than 30,000 hours of ASTM B117-19 salt sea spray testing with no observed corrosion is a significant validation of THERMAL-XR® ENHANCE in one of the harshest standard corrosion test environments available. To put this in context, many premium automotive, building and industrial coatings are benchmarked at around 1,000 hours, and high-performance marine and offshore systems at 2,000 hours or more, with extended programmes for some advanced systems reaching into the low thousands of hours. By surpassing 30,000 hours in continuous salt spray testing while also delivering improved heat transfer under high air-flow conditions, THERMAL-XR® ENHANCE demonstrates truly next-generation performance in both corrosion protection and heat-exchange efficiency."

GMG's Chairman and Non-Executive Director, Jack Perkowski, commented: "It is fantastic to see THERMAL-XR® ENHANCE providing measurable benefits in such an important application - space cooling, refrigeration and data centres in demanding operating and environmental conditions. These results, combined with our growing regulatory approvals and distribution footprint, give us confidence in the role THERMAL-XR® can play as a global benchmark coating for energy savings and corrosion protection."

THERMAL-XR® ENHANCE Development and EPA Approval History

MonthSignificant Milestones for THERMAL-XR® powered by GMG GrapheneSeptember 2022GMG acquires THERMAL-XR® manufacturing intellectual property and brand rights
GMG ACQUIRES THERMAL-XR MANUFACTURING INTELLECTUAL PROPERTY AND BRAND RIGHTS AND GRANTS RSUs TO DIRECTORS AND OFFICERS - Graphene Manufacturing Group | GMG (graphenemg.com)December 2022Verified Improved Heat Transfer by The University of Queensland.
VERIFIED IMPROVED HEAT TRANSFER ON ALUMINIUM WITH THERMAL-XR® & MARKET UPDATE - Graphene Manufacturing Group | GMG (graphenemg.com)February 2023Approval from Australian Industrial Chemicals Introduction Scheme (AICIS)
GMG RECEIVES REGULATORY APPROVAL TO ENABLE SIGNIFICANT COMMERCIAL SALES - Graphene Manufacturing Group | GMG (graphenemg.com)April 2023Total available market for THERMAL-XR® estimated by Company to be > US$28.4 billion
GMG ANNOUNCES COMMERCIALISATION PROGRESS OF THERMAL-XR® - Graphene Manufacturing Group | GMG (graphenemg.com)April 2023First order of THERMAL-XR® > $120,000
GMG ANNOUNCES COMMERCIALISATION PROGRESS OF THERMAL-XR® - Graphene Manufacturing Group | GMG (graphenemg.com)May 2023Signing of Distributors for Singapore, Thailand, Indonesia & South Korea
GMG SIGNS THERMAL-XR® DISTRIBUTOR AGREEMENTS IN 4 ASIAN COUNTRIES - Graphene Manufacturing Group | GMG (graphenemg.com)June 2023Independently Verified Heat Transfer & Energy Savings
GMG ANNOUNCES INDEPENDENTLY VERIFIED HEAT TRANSFER AND ENERGY SAVINGS RESULTS FROM THERMAL-XR® - Graphene Manufacturing Group | GMG (graphenemg.com)July 2023Signing of Nu-Calgon Distribution for North America - USA, Canada, Mexico, & Caribbean.
GMG APPOINTS NU-CALGON AS THERMAL-XR® DISTRIBUTOR FOR NORTH AMERICA - Graphene Manufacturing Group | GMG (graphenemg.com)August 2023Commissioning of THERMAL-XR® Coating Bulk Blend Plant
GMG PROVIDES COMMERCIALISATION PROGRESS OF THERMAL-XR® - Graphene Manufacturing Group | GMG (graphenemg.com)October 2023Forward Orders > AU$ 400k - Conditional on Import Approvals for some Countries
GMG PROVIDES COMMERCIALISATION UPDATE ON ENERGY SAVINGS COATING THERMAL-XR® - Graphene Manufacturing Group | GMG (graphenemg.com)December 2023Commissioning of the modular Graphene Production plant
Graphene Manufacturing Group Commissions Modular Graphene Production Plant - Graphene Manufacturing Group | GMG (graphenemg.com)January 2024Canada Approval Department of Environment and Climate Change Canada (ECCC)January 2024Launch of Nu-Calgon CoolWorx® powered by GMG Graphene at Chicago AHR Expo 2024.
Launch of Nu-Calgon CoolWorx® powered by GMG Graphene at Chicago AHR Expo 2024.April 2024GMG Provides Commercialisation Update on Energy Savings Coating THERMAL-XR®
GMG Provides Commercialisation Update on Energy Savings Coating THERMAL-XR®December 2024GMG Reaches Market Commercialisation Milestone on Energy Savings Coating THERMAL-XR®
GMG Reaches Market Commercialisation Milestone on Energy Savings Coating THERMAL-XR®December 2025USA EPA Approval Conditions Accepted for Graphene Coating THERMAL-XR®
USA EPA Approval Conditions Accepted for Graphene Coating THERMAL-XR®December 2025USA EPA Approval Conditions Accepted for Graphene Coating THERMAL-XR®
USA EPA Approval Conditions Accepted for Graphene Coating THERMAL-XR®March 2026THERMAL-XR® Sales in the United States to Commence after GMG Receives US EPA Approval
THERMAL-XR® Sales in the United States to Commence after GMG Receives US EPA ApprovalJune 2026GMG Delivers its first ever bulk shipment of THERMAL-XR® to Nu Calgon in the USA
GMG Delivers its first ever bulk shipment of THERMAL-XR® to Nu Calgon in the USAAbout THERMAL-XR® ENHANCE powered by GMG Graphene:

THERMAL-XR® ENHANCE coating system is a unique method of improving the conductivity of corroded heat exchange surfaces and improving and maintaining the performance of new units at peak levels. The process coats and protects heat exchange surfaces while improving and rebuilding the lost corroded thermal conductivity and increasing the heat transfer rate by leveraging the physics of GMG Graphene, resulting in an efficiency improvement and a potential power reduction.

THERMAL-XR® ENHANCE is now patented for 20 years in Australia and is expected to be patented in other countries around the world.

About GMG:

GMG is an Australian based clean-technology company which develops, makes and sells energy saving and energy storage solutions, enabled by graphene manufactured via in house production process. GMG uses its own proprietary production process to decompose natural gas (i.e. methane) into its natural elements, carbon (as graphene), hydrogen and some residual hydrocarbon gases. This process produces high quality, low cost, scalable, 'tuneable' and low/no contaminant graphene suitable for use in clean-technology and other applications.

The Company's present focus is to de-risk and develop commercial scale-up capabilities, and secure market applications. In the energy savings segment, GMG has initially focused on graphene enhanced heating, ventilation and air conditioning ("HVAC-R") coating (or energy-saving coating) which is now being marketed into other applications including electronic heat sinks, industrial process plants and data centres. Another product GMG has developed is the graphene lubricant additive focused on saving liquid fuels initially for diesel engines.

In the energy storage segment, GMG and the University of Queensland are working collaboratively with financial support from the Australian Government to progress R&D and commercialization of graphene aluminium-ion batteries ("G+AI Batteries"). GMG has also developed a graphene additive slurry that is aimed to improve the performance of lithium-ion batteries.

GMG's 4 critical business objectives are:

Produce Graphene and improve/scale cell production processesBuild Revenue from Energy Savings ProductsDevelop Next-Generation Battery Develop Supply Chain, Partners & Project Execution CapabilityNeither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this news release.

Cautionary Note Regarding Forward-Looking Statements

This news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends", "expects", "anticipates", "plans", "estimates" or "believes", or variations of such words and phrases, or statements that certain actions, events or results "may", "could", "should", "would" or will "potentially" or "likely" occur. These statements, referred to herein as "forward-looking statements", are not historical facts and are made as of the date of this news release.

Forward-looking statements in this news release include, without limitation, statements regarding: the Company's expectations relating to the performance, durability, energy savings and enhanced corrosion resistance of the THERMAL-XR® ENHANCE graphene coating product in commercial applications; the Company's belief that THERMAL-XR® ENHANCE represents next-generation heat transfer technology and a global benchmark coating; the anticipated benefits of THERMAL-XR® ENHANCE in radiators, HVAC-R systems, engine cooling and other industrial and building applications; the Company's expectations regarding market demand and commercialisation of THERMAL-XR® ENHANCE and related products (including Nu-Calgon CoolWorx® powered by GMG Graphene); references to typical ASTM B117-19 salt spray benchmark durations for premium automotive, building, industrial, marine and offshore coatings and statements comparing those benchmarks to THERMAL-XR® ENHANCE's extended salt spray test duration; and the Company's regulatory and commercialisation plans in the United States and other jurisdictions, including the implications of approvals or consent orders from regulators such as the United States Environmental Protection Agency (EPA) and the Department of Environment and Climate Change Canada (ECCC), GMG's intentions to develop commercial scale-up capabilities, GMG's focus in the energy savings segment, GMG's intentions for the use of graphene lubricant additive on saving liquid fuels, expectations for R&D and commercialisation of G+AI Batteries, GMG's ability to improve the performance of lithium-ion batteries and the Company's four critical business objectives.

Such forward-looking statements are based on a number of assumptions of management, including, without limitation: that the results observed in laboratory salt sea spray testing and other technical evaluations of THERMAL-XR® ENHANCE (including extended ASTM B117-19 test durations) will be indicative of performance in real-world commercial operating conditions; that THERMAL-XR® ENHANCE will continue to perform as expected over extended periods; that comparisons to typical salt spray benchmark durations for other coatings are a useful indicator of relative corrosion-resistance performance, recognising that ASTM B117-19 is an accelerated, comparative test method and not a direct predictor of in-service lifespan; that regulatory approvals, consent notices and other permissions (including those from the EPA, ECCC and other national or regional authorities) will remain in effect on terms acceptable to the Company; that the Company and its distributors will be able to market, sell and deliver THERMAL-XR® ENHANCE and related products into target markets as planned; that sufficient customer demand will develop for energy-saving and corrosion-protection coatings at the performance levels contemplated; and that the Company's cash position, access to capital and business fundamentals will remain supportive of its commercialisation plans.

Additionally, forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of GMG to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: the risk that laboratory test results, including salt sea spray testing duration and performance, do not translate into equivalent real-world performance; the risk that extended salt spray test durations may be misinterpreted as direct indicators of product life in service; technical de-risking and market acceptance risks for THERMAL-XR® ENHANCE and other products; construction, scale-up, manufacturing and supply chain risks; the risk that required approvals, consent notices or permits are not received, are delayed, are revoked or are received or maintained on terms that are not acceptable to the Company (including from the EPA, ECCC and other regulators); changes in environmental, chemical or product-safety regulations; competitive product and technology developments; overall economic conditions and capital market volatility; foreign exchange fluctuations; and the risk factors set out under the heading "Risk Factors" in the Company's annual information form dated November 4, 2025 available for review on the Company's profile at www.sedarplus.ca.

Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that is incorporated by reference herein, except as required by applicable securities laws.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/304571

Source: Graphene Manufacturing Group Ltd.

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

~ Updated clearance incorporates various instrument upgrades, as well as per-procedure costs, improving unit economics driven by the reclassification of certain instruments from disposable to reusable status ~

~ Clearance reflects Tenon's commitment to continuous innovation and operational efficiency, with reusable instrumentation expected to drive lower capex and logistical spend, contributing positively to gross margins and cash flow ~

LOS GATOS, CA / ACCESS Newswire / July 2, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering with certain sacro-pelvic disorders, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Catamaran® SI Joint Fusion System.

The updated clearance incorporates various instrument upgrades, as well as the reclassification of certain instruments from disposable to reusable status. These enhancements are designed to further improve the performance of the Catamaran System while delivering meaningful economic benefits to the Company by eliminating ongoing per-procedure costs previously associated with disposable instrumentation.

"This 510(k) clearance reflects our ongoing commitment to never-ending refinement of our Catamaran System - not only for the physicians who rely on it and the patients who depend on it, but also for the long-term financial health of our business," said Steven M. Foster, President and CEO of Tenon. "The instrument upgrades advance the procedural performance that our surgeon users have come to expect from the Catamaran platform, and the transition of select instruments from disposable to reusable status is a smart operational improvement that will reduce our per-procedure cost structure and contribute positively to our gross margins going forward. As we continue to drive commercial adoption across our growing portfolio, initiatives like this demonstrate that we are focused on building a sustainable, scalable business."

The Catamaran SI Joint Fusion System offers a novel, minimally invasive approach to the sacroiliac joint, utilizing a single, robust titanium implant that stabilizes and transfixes the SI joint along its longitudinal axis. The implant's inferior-posterior surgical approach is designed to navigate away from critical neural and vascular structures and into the strongest cortical bone. Since its national launch in October 2022, there have been over 1,500 Catamaran Fixation Devices implanted in patients throughout the United States suffering from sacroiliac joint disruptions and degenerative sacroiliitis.

About Tenon Medical, Inc.

Tenon Medical, Inc. is a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders. Tenon was incorporated in the State of Delaware in 2012 and currently offers two systems to treat a diseased sacroiliac joint (the "SI Joint"). The Company has developed The Catamaran™ SI Joint Fusion System that offers a novel, less invasive approach to the SI Joint using a single, robust titanium implant. In August 2025, the Company acquired substantially all of the assets of SiVantage, Inc. and SIMPL Medical, LLC, including the SImmetry+® SI Joint Fusion System, which treats disorders of the SI Joint through a minimally invasive lateral access solution that incorporates well-established orthopedic fusion principles. Since the national launch of The Catamaran System in October 2022, Tenon is focused on three commercial opportunities: 1) primary SI Joint procedures, 2) revision procedures of failed SI Joint implants and 3) SI-Joint fusion adjunct to a spine fusion construct.

For more information, please visit www.tenonmed.com. Information on the Company's website does not constitute a part of and is not incorporated by reference into this press release.

The Tenon Medical logo shown above, and Catamaran®, PiSIF®, CAT PiSIF®, ETAD®, Posterior Inferior Sacroiliac Fusion®, CAT SIJ Fusion System®, Catamaran SIJ Fusion System®, Catamaran Inferior Posterior Fusion System®, Catamaran Transfixation Fusion System®, Catamaran Transfixation Fusion Device®, SImmetry® are registered trademarks of Tenon Medical, Inc. MAINSAILTM, and SImmetry+ are also trademarks of Tenon Medical, Inc.

Safe Harbor

This press release contains "forward-looking statements," which are statements related to events, results, activities or developments that Tenon expects, believes or anticipates will or may occur in the future. Forward-looking often contains words such as "intends," "estimates," "anticipates," "hopes," "projects," "plans," "expects," "seek," "believes," "see," "should," "will," "would," "target," and similar expressions and the negative versions thereof. These forward-looking statements, include, but are not limited to, statements regarding the completion of the Offering, the satisfaction of customary closing conditions related to the Offering and the anticipated use of proceeds therefrom. Such statements are based on Tenon's experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances, and speak only as of the date made. Forward-looking statements are inherently uncertain and actual results may differ materially from assumptions, estimates or expectations reflected or contained in the forward-looking statements as a result of various factors. For details on the uncertainties that may cause Tenon's actual results to be materially different than those expressed in any forward-looking statements, please review Tenon's Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and updated from time to time in our Form 10-Q filings and in our other public filings on file with the SEC at www.sec.gov statements contain, particularly the information contained in the section entitled "Risk Factors." We undertake no obligation to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise unless required by law.

IR Contact:
Shannon Devine
203-741-8811
MZ North America
[email protected]

SOURCE: Tenon Medical, Inc.

Expanded Visibility Among Institutional Investors Expected to Reflect Growing Value for Customers and Shareholders

MORRISVILLE, NC / ACCESS Newswire / July 1, 2026 / 374Water Inc. (NASDAQ:SCWO) ("374Water" or the "Company"), a leading cleantech and environmental services company deploying supercritical water oxidation technology for the permanent destruction of organic waste through its proprietary AirSCWO™, today announced that it has been added to the Russell Microcap® Index following the annual Russell U.S. Indexes reconstitution, effective after the close of U.S. markets on June 26, 2026.

"We are excited to be included in the Russell Microcap Index," said Danny Bogar, Chief Executive Officer of 374Water. "We expect that the visibility this gives our Company will amplify the value we create for our customers. We have made material progress in executing our commercial strategy and growing 374Water's presence in the market, and creating value within the investment community and to our investor base. As we continue to deploy our AirSCWO technology, expand our Waste Destruction as a Service platform, and establish strategic partnerships, we remain focused on creating long-term shareholder value by addressing one of the world's most pressing environmental challenges.

While inclusion in the Russell Microcap Index enhances our visibility among institutional investors, our focus remains unchanged: execute commercial deployments, grow recurring Waste Destruction Services revenue, and build out our leading platform for PFAS destruction."

The Russell Microcap® Index measures the performance of the microcap segment of the U.S. equity market and is widely used by investment managers and institutional investors as a benchmark for investment strategies and index-based funds.

374Water's AirSCWO technology and established Waste Destruction Services platform provides a strong commercial base for value creation, both for a broad base of customers across sectors and a new and established investor base. The demand for permanent destruction of PFAS, biosolids, industrial waste, landfill leachate, firefighting foam, and other organic waste streams supports strong growth projections.

About 374Water

374Water Inc. (NASDAQ:SCWO) is a cleantech environmental services company providing innovative solutions addressing wastewater treatment and waste management issues within the industrial, municipal, and federal markets. 374Water's AirSCWO technology is designed to efficiently destroy and mineralize a broad spectrum of nonhazardous and hazardous organic wastes, producing safe dischargeable water streams, safe mineral effluent, safe vent gas, and recoverable heat energy. 374Water's AirSCWO technology has the potential to assist its customers to meet discharge requirements, reduce or eliminate disposal costs, remove bottlenecks, and reduce litigation and other risks. 374Water continues to be a leader in innovative waste treatment solutions, dedicated to creating a greener future and eradicating harmful pollutants. Learn more by visiting www.374water.com and follow us on LinkedIn.

Forward-Looking Statements

Certain statements in this communication are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "anticipate," "believe," "confidence," "could," "design," "estimate," "expect," "intend," "may," "plan," "predict," "project," "potential," or other comparable terminology are intended to identify forward-looking statements, including, without limitation, 374Water's expectations regarding Phase 2 performance, the development of follow-on mobile deployments, the potential for multiple millions of dollars in revenue from Minnesota operations, and its estimate that a single mobile AirSCWO system has the potential to generate between $500,000 and $1.5 million in annual revenue depending on deployment cadence, waste stream composition, and contract structure. 374Water has based these forward-looking statements on its current expectations, assumptions, estimates, beliefs, and projections. While 374Water believes these expectations, assumptions, estimates, and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which involve factors or circumstances that are beyond 374Water's control. These forward-looking statements are subject to risks and uncertainties, including those discussed under "Risk Factors" in 374Water's Form 10-K for the year ended December 31, 2025, and in 374Water's subsequent filings and reports with the SEC. The forward-looking statements herein are made only as of the date they were first issued, and unless otherwise required by laws, 374Water disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Investor Relations Contact

Belton Copp
Vice President
Direct: 401-419-1545
[email protected]
www.374Water.com

SOURCE: 374Water Inc.

BOULDER, CO / ACCESS Newswire / June 30, 2026 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader in hypochlorous acid (HOCl) technology, today announced it has received a new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Microdacyn® Wound Irrigation Solution, including expanded claims, clearance for multiple use, and additional packaging configurations.

Under this new clearance, Microdacyn Wound Irrigation Solution can be used under the supervision of a healthcare professional for cleansing, irrigating, moistening, debridement and removal of foreign material including microorganisms from exudating and/or dirty wounds, acute and chronic dermal lesions, such as Stage I-IV pressure ulcers, stasis ulcers, diabetic ulcers, post‑surgical wounds, first and partial thickness second degree burns, abrasions, minor irritations of the skin, diabetic foot ulcers, ingrown toe nails, grafted and donor sites, and exit sites, and for moistening and lubricating absorbent wound dressings.

Microdacyn Wound Irrigation Solution can also be used for OTC management of minor skin abrasions, minor lacerations, minor irritations and intact skin of the face, eyelid and eyelashes.

The new 510(k) clearance expands the use case to single patient, multiple use.

The 510(k) also adds new packaging configurations, including 4 oz, 8 oz, 16 oz, and 34 oz PET bottles with a polypropylene flip-top cap, and a 4 oz PET bottle with polypropylene sprayer or spray gun, each with a 24-month shelf life.

"This expanded FDA clearance is another example of how we continue to strengthen the value of our Microcyn technology platform," said Amy Trombly, CEO of Sonoma Pharmaceuticals. "By broadening product claims, adding multiple-use labeling and introducing new packaging options, we are creating additional opportunities for our commercial partners while increasing the attractiveness of our wound care portfolio to prospective distributors and private-label customers. We remain committed to regulatory investment as it provides an important competitive advantage for Sonoma and supports our long-term growth strategy."

About Sonoma Pharmaceuticals, Inc.

Sonoma Pharmaceuticals is a global healthcare company specializing in stabilized hypochlorous acid (HOCl) technology for medical, veterinary and consumer healthcare applications. With decades of expertise in HOCl formulation, manufacturing and regulatory science, Sonoma helps healthcare companies develop, manufacture and commercialize innovative products through contract development, regulatory support and commercial manufacturing.

The company's patented Microcyn® technology platform supports a broad range of applications, including wound care, burn care, dermatology, senior and baby care, podiatry, eye care, oral care and animal health. Sonoma's regulatory portfolio includes 23 FDA 510(k) clearances, along with product registrations and approvals in markets around the world, providing commercial partners with an established pathway to market.

Headquartered in Boulder, Colorado, Sonoma operates a high-capacity manufacturing facility in Guadalajara, Mexico, and European commercial headquarters in Roermond, Netherlands. The company supports commercial partners in more than 55 countries and is actively expanding its global partner network.

For partnership opportunities, including contract development, licensing, commercial manufacturing and distribution, please contact [email protected]. More information is available at www.sonomapharma.com.

Forward-Looking Statements

Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the "company"). These forward-looking statements are identified by the use of words such as "continue," "develop," "anticipate," "expect" and "opportunities," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company's products will not be as large as expected, the company's products will not be able to penetrate one or more targeted markets, and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law.

Sonoma Pharmaceuticals™, Microcyn® and Microdacyn® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.

Media and Investor Contact:
Sonoma Pharmaceuticals, Inc.
[email protected]

Website: www.sonomapharma.com
Follow us on LinkedIn: https://www.linkedin.com/company/sonoma-pharmaceuticals
Follow us on Instagram: https://www.instagram.com/sonomapharma_us/
Follow us on Facebook: https://www.facebook.com/sonomapharma/

SOURCE: Sonoma Pharmaceuticals, Inc.

ORLANDO, FL / ACCESS Newswire / June 29, 2026 / Unusual Machines, Inc. (NYSE American:UMAC), a leading manufacturer of NDAA-compliant drone components, today announced it has been added to the Russell 2000® Index as part of the first 2026 Russell indexes reconstitution. The Company was previously included in the Russell Microcap® Index.

The move reflects the Company's continued expansion as it increases U.S.-based manufacturing capacity and builds a more controlled, compliant drone component supply chain.

The Russell 2000® Index measures the performance of approximately 2,000 small-cap U.S. companies and is widely used by investment managers and institutional investors as a benchmark for small-cap equity portfolios.

"We've been focused on building a business that can deliver, expanding production capacity, strengthening the supply chain, and staying ready to meet demand," said Allan Evans, Chief Executive Officer of Unusual Machines. "Inclusion in the Russell 2000 reflects that progress and increases our visibility with a broader group of institutional investors."

About Unusual Machines, Inc.

Unusual Machines manufactures and sells drone components and drones across a diversified brand portfolio, which includes Fat Shark, the leader in FPV (first-person view) ultra-low latency video goggles for drone pilots. The Company also retails small, acrobatic FPV drones and equipment directly to consumers through the curated Rotor Riot ecommerce store. With a changing regulatory environment, Unusual Machines seeks to be a dominant Tier-1 parts supplier to the fast-growing multi-billion-dollar U.S. drone industry. According to Fact.MR, the global drone accessories market is currently valued at $17.5 billion and is set to top $115 billion by 2032. For more information, please visit unusualmachines.com.

Investor Contact:
[email protected]

Media Contact:
[email protected]

SOURCE: Unusual Machines, Inc.

Inclusion Expected to Take Effect Following the U.S. Market Close Today, June 26, 2026

FISHERS, IN / ACCESS Newswire / June 26, 2026 / American Resources Corporation (NASDAQ:AREC) ("American Resources" or the "Company"), a leader in the critical mineral supply chain, today announced that the Company is set to be added to both the Russell 3000® Index and the Russell Microcap® Index as part of the 2026 Russell indexes reconstitution.

FTSE Russell's preliminary 2026 additions lists include American Resources Corporation under the symbol AREC for both the Russell 3000 Index and Russell Microcap Index. The newly reconstituted Russell indexes are expected to take effect following the close of the U.S. market today, Friday, June 26, 2026.

"American Resources is pleased to be included in the Russell 3000 and Russell Microcap Index reconstitution," stated Mark LaVerghetta, Director of American Resources Corporation. "We believe this milestone reflects the continued evolution of American Resources and enhances the Company's visibility within the institutional investment community. As we advance our strategy across critical mineral feedstock sourcing, processing, trading and strategic investments, we remain focused on creating long-term value for our shareholders while supporting the secure domestic and allied supply chains required by advanced manufacturing, defense, energy and other strategic markets."

Membership in the Russell 3000 Index and Russell Microcap Index provides inclusion within widely followed benchmarks used by investment managers and institutional investors for index funds and related investment products. The Russell 3000 Index is designed to represent approximately 98% of the investable U.S. equity market, while the Russell Microcap Index is designed to capture the microcap segment of the U.S. equity market.

About American Resources Corporation (NASDAQ:AREC)

American Resources Corporation has established a comprehensive solution platform across the rare earth and critical mineral supply chain, leveraging its affiliation with, and former parent relationship to, ReElement Technologies Corporation - a leading provider of high-performance refining capacity for rare earth and critical battery elements. The Company is advancing efficient upstream and downstream critical mineral operations.

These operations span conventional and unconventional resource sourcing and development, as well as recycling and manufacturing, enabling American Resources to aggregate and process diverse feedstocks while efficiently aligning supply with end-market demand.

American Resources has established a nimble, low-cost business model focused on scalable growth. Its streamlined approach enables the Company to expand its asset portfolio and meet increasing global demand across infrastructure, defense, technology, and electrification markets - while maximizing margins and maintaining cost discipline. For more information visit americanresourcescorp.com or connect with the Company on Facebook, Twitter, and LinkedIn.

Special Note Regarding Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that could cause the Company's actual results, performance, or achievements or industry results to differ materially from any future results, performance, or achievements expressed or implied by these forward-looking statements. These statements are subject to a number of risks and uncertainties, many of which are beyond American Resources Corporation's control. The words "believes", "may", "will", "should", "would", "could", "continue", "seeks", "anticipates", "plans", "expects", "intends", "estimates", or similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. Any forward-looking statements included in this press release are made only as of the date of this release. The Company does not undertake any obligation to update or supplement any forward-looking statements to reflect subsequent events or circumstances. The Company cannot assure you that the projected results or events will be achieved.

Company Contact:

Mark LaVerghetta
317-855-9926 ext. 0
[email protected]

SOURCE: American Resources Corporation

Collaboration with Fear Free and Zomedica reinforces Assisi Loop tPEMF™ therapy as a low-stress option for pets.

ANN ARBOR, MI / ACCESS Newswire / June 25, 2026 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), an animal health company offering innovative point-of-care diagnostic and therapeutic products for equine and companion animals, today announced the renewal of the alliance between the Assisi® brand and Fear Free, the initiative dedicated to preventing and alleviating fear, anxiety, and stress (FAS) in pets.

The renewed agreement reinforces a shared commitment to improving the emotional and physical wellbeing of companion animals by integrating innovative therapies with Fear Free's science-based approach to low-stress handling and care.

"Renewing our partnership with Fear Free reflects our continued dedication to transforming the veterinary experience for pets, pet parents, and veterinary professionals," said Mialisa Gluckert, Senior Director of Product Commercialization at Zomedica. "With the Assisi devices, we are helping practices and pet owners adopt solutions that reduce stress while improving clinical outcomes."

Through this collaboration, Zomedica and Fear Free will continue to:

Educate veterinary professionals on incorporating stress-reducing protocols alongside therapeutic technologies

Expand awareness of non-invasive treatment options, including tPEMF therapy, for pain and inflammation management

Support pet parents with products that promote calmer, more positive care experiences for their animals

The Fear Free certification programs and educational resources have transformed how veterinary teams approach patient care by prioritizing emotional wellbeing. The Assisi therapeutic devices, including the Assisi Loop®,Assisi EquiLoop®, DentaLoop®, Loop Lounge®, and Calmer Canine® products complement these efforts by offering drug-free solutions that can be administered comfortably in low-stress environments.

"Fear Free is committed to reducing Fear, Anxiety, and Stress (FAS) and improving the wellbeing of pets through emotionally considerate care. We are excited to continue our alliance with Zomedica and support solutions that can be incorporated into a lower-stress care experience," said Natalie Gruchow, Corporate Programs & Product Specialists at Fear Free.

The renewal underscores both organizations' ongoing mission to raise the standard of care within veterinary medicine while strengthening the human-animal bond.

For more information about the Assisi line of products, visit: https://zomedica.com/our-brands/assisi/

About Zomedica

Zomedica is a leading equine and companion animal healthcare company dedicated to improving animal health by providing veterinarians with innovative therapeutic and diagnostic solutions. Our gold standard PulseVet® shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Our suite of products also includes the Assisi Loop® line of therapeutic devices and the TRUFORMA® diagnostic platform, the TRUVIEW® digital cytology system, the VetGuardian PLUS™ Zero TouchTM monitoring system and VETIGEL® hemostatic gel, all designed to empower veterinarians to provide top-tier care. In the aggregate, their total addressable market in the U.S. exceeds $2 billion. Headquartered in Michigan, Zomedica employs approximately 150 people and manufactures and distributes its products from its world-class facilities in Georgia and Minnesota. Zomedica grew revenue 17% in 2025 to $32 million and maintains a strong balance sheet with approximately $48 million in liquidity as of March 31, 2026. Zomedica is advancing its product offerings, leveraging strategic acquisitions, and expanding internationally as we work to enhance the quality of care for pets, increase pet parent satisfaction, and improve the workflow, cash flow and profitability of veterinary practices. For more information visit www.zomedica.com.

About Fear Free

Founded in 2016, Fear Free is a recognized leader in improving the emotional wellbeing of animals by educating and empowering those who care for them to help prevent and alleviate Fear, Anxiety, and Stress (FAS). Through continuing education, certification programs, and practical tools, Fear Free supports veterinary teams, pet care providers, and pet caregivers worldwide in delivering compassionate care. With a growing global community, Fear Free continues to expand its impact on how care is delivered. Learn more at fearfree.com.

Follow Zomedica

Email Alerts: http://investors.zomedica.com

LinkedIn: https://www.linkedin.com/company/zomedica

Facebook: https://m.facebook.com/zomedica

X (formerly Twitter): https://twitter.com/zomedica

Instagram: https://www.instagram.com/zomedica_inc

Cautionary Note Regarding Forward-Looking Statements

Except for statements of historical fact, this news release contains certain "forward-looking information" or "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.

Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements and our ability to realize upon our business plans and cost control efforts.

Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: uncertainty as to whether demand for development services will continue; the outcome of clinical studies; the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments; uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, including international efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to realize the anticipated growth opportunities from our acquisitions; uncertainty as to our ability to supply products in response to customer demand; supply chain risks associated with tariff changes; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products and purchase of consumables following adoption of our capital equipment; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR+ at www.sedarplus.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.

The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.

Investor Relations Contact:

Zomedica Investor Relations
[email protected]
1-734-369-2555

SOURCE: Zomedica Corp.

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.

The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.

It also includes access to the Zacks Style Scores.

What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.

Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.

Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.

Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.

VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.

How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.

#1 (Strong Buy) stocks have produced an unmatched +24% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.

But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.

That's where the Style Scores come in.

You want to make sure you're buying stocks with the highest likelihood of success, and to do that, you'll need to pick stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you like a stock that only has a #3 (Hold) rank, it should also have Scores of A or B to guarantee as much upside potential as possible.

As mentioned above, the Scores are designed to work with the Zacks Rank, so any change to a company's earnings outlook should be a deciding factor when picking which stocks to buy.

A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Ryder (R - Free Report) Ryder System, Inc., a Florida-based corporation founded in 1933, is recognized as one of the world's largest providers of integrated logistics and transportation solutions. Ryder’s customers range from small businesses to large international enterprises. They are drawn from a wide variety of industries, the most significant of which include automotive, electronics, transportation, grocery, lumber and wood products, food service and home furnishing.

R is a #2 (Buy) on the Zacks Rank, with a VGM Score of A.

Momentum investors should take note of this Transportation stock. R has a Momentum Style Score of B, and shares are up 7.9% over the past four weeks.

For fiscal 2026, two analysts revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.59 to $14.82 per share. R boasts an average earnings surprise of +4%.

With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, R should be on investors' short list.

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.

The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.

Zacks Premium includes access to the Zacks Style Scores as well.

What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.

Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.

Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.

Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.

VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.

How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.

#1 (Strong Buy) stocks have produced an unmatched +24% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.

This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.

That's where the Style Scores come in.

To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.

The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.

For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Ryder (R - Free Report) Ryder System, Inc., a Florida-based corporation founded in 1933, is recognized as one of the world's largest providers of integrated logistics and transportation solutions. Ryder’s customers range from small businesses to large international enterprises. They are drawn from a wide variety of industries, the most significant of which include automotive, electronics, transportation, grocery, lumber and wood products, food service and home furnishing.

R is a #3 (Hold) on the Zacks Rank, with a VGM Score of A.

Additionally, the company could be a top pick for growth investors. R has a Growth Style Score of B, forecasting year-over-year earnings growth of 14.7% for the current fiscal year.

For fiscal 2026, one analyst revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.47 to $14.82 per share. R boasts an average earnings surprise of +4%.

With a solid Zacks Rank and top-tier Growth and VGM Style Scores, R should be on investors' short list.

MIAMI--(BUSINESS WIRE)--Ryder System, Inc. (NYSE: R) today announced the winners of its 54th annual Driver of the Year award, recognizing three professional drivers whose commitment to excellence in safety, customer service, and leadership exemplifies the best of Ryder’s operations across its supply chain, dedicated transportation, and fleet management businesses.

“Ryder professional drivers do far more than deliver freight — they set the standard for how our company shows up every day.”

Share The honorees—Tamara “Tammy” Land, Robert Deroy, and Terry Frey—bring decades of combined experience and millions of safe miles to the road. Each has earned a reputation for excellence behind the wheel and for the positive impact they make on customers, teammates, and the communities they serve. As part of this honor, all three drivers are inducted into the Ryder Driver Hall of Fame.

“Ryder professional drivers do far more than deliver freight — they set the standard for how our company shows up every day,” said Ryder CEO John Diez. “Tammy, Robert, and Terry embody what it means to lead with professionalism, put safety first, and take pride in serving others. Their dedication reflects the strength of our culture and the trust our customers place in Ryder.”

Tammy Land | Supply Chain Solutions

Based in Waterloo, Iowa, Tammy Land is Ryder’s Supply Chain Solutions Driver of the Year, bringing more than 32 years of professional driving experience, including five years with Ryder. Over her career, she has logged more than 2.2 million miles, including 415,000 miles driven with Ryder, while maintaining an exceptional safety record.

A Ryder Certified Driver Trainer, and known for her steady leadership and proactive communication, Land plays a key role in mentoring new drivers and reinforcing Ryder’s safety culture from day one. Beyond her work, Land is actively involved in community and volunteer efforts, including wildlife rehabilitation and breast cancer awareness.

Robert Deroy | Dedicated Transportation Solutions

Supporting a Ryder customer out of West Palm Beach, Fla., Robert Deroy is the Dedicated Transportation Solutions Driver of the Year, bringing 25 years of professional driving experience, including 15 years with Ryder. Since joining the company in 2010, Deroy has logged nearly 1.3 million miles with Ryder and nearly 2.2 million miles over his career, distinguishing himself as a leader in safety, training, and operational excellence.

A long‑standing Certified Driver Trainer, Smith System Trainer, and American Red Cross CPR, AED, and First Aid instructor, Deroy is known for being one of Ryder’s most trusted drivers in high‑stakes, safety‑critical situations and specialized operations. In his spare time, he is deeply engaged in community support activities, including emergency response and disaster‑relief efforts.

Terry Frey | Fleet Management Solutions

Operating out of Conestoga, Penn., Terry Frey is the recipient of Ryder’s Fleet Management Solutions Driver of the Year award, which recognizes customer drivers who go above and beyond to keep roads safe while operating Ryder vehicles. Frey brings 34 years of professional driving experience, including more than 26 years supporting a Ryder‑managed fleet for Turkey Hill Dairy. Over his career, he has logged nearly 2.5 million miles, including more than 2 million miles at Turkey Hill Dairy.

Known for his reliability, professionalism, and attention to detail, Frey is widely respected by Ryder technicians, customer teams, and fellow drivers. Beyond his work, Frey is deeply involved in his local community, where he has spent years mentoring young people and supporting nonprofit organizations focused on youth development and character building.

About Ryder System, Inc.

Ryder System, Inc. (NYSE: R) is a nearly $13 billion leading provider of outsourced logistics and transportation services throughout the United States, Canada, and Mexico. Ryder offers supply chain, dedicated transportation, and fleet management solutions that integrate every step of the supply chain port‑to‑door, including cross-border logistics, fleet and transportation management, warehousing and distribution, and final delivery to customers’ doorsteps. Ryder’s broad portfolio of services encompasses managed transportation, freight brokerage, dedicated contract carriage with professional drivers, full‑service fleet leasing and maintenance, commercial truck rental, automation and robotics, digital technologies, contract manufacturing and packaging, omnichannel retail fulfillment including e-commerce and last-mile delivery, and used vehicle sales. Serving more than 20 industries, Ryder manages approximately 240,000 commercial vehicles, operates nearly 800 maintenance locations, and runs approximately 320 warehouses totaling more than 100 million square feet. Ryder is consistently recognized for technology‑driven innovation and industry‑leading practices in safety, health, security, talent acquisition, and environmental management, and was most recently named to Fortune’s “America’s Most Innovative Companies” list. www.ryder.com

Note Regarding Forward-Looking Statements: Certain statements and information included in this news release are “forward-looking statements” within the meaning of the Federal Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on our current plans and expectations and are subject to risks, uncertainties and assumptions. Accordingly, these forward-looking statements should be evaluated with consideration given to the many risks and uncertainties that could cause actual results and events to differ materially from those in the forward-looking statements including those risks set forth in our periodic filings with the Securities and Exchange Commission. New risks emerge from time to time. It is not possible for management to predict all such risk factors or to assess the impact of such risks on our business. Accordingly, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

ryder-ar

More News From Ryder System, Inc.

Inclusion reflects the growing convergence of loyalty, promotions, rewards, and first-party customer intelligence in the modern customer engagement landscape

VANCOUVER, BC / ACCESS Newswire / June 17, 2026 / Snipp Interactive Inc. ("Snipp" or the "Company") (TSX-V:SPN)(OTCPK:SNIPF), a value-added SaaS company and leader in shopper marketing promotions, loyalty programs, and purchase validation technology, today announced it has been named a Representative Vendor in the Gartner® 2026 Market Guide for Loyalty Program Vendors in the Multisolution Vendor category. This inclusion places Snipp among vendors included in the report and underscores the company's growing presence at the intersection of loyalty, promotions, and data-driven customer engagement.

The Gartner Market Guide evaluates vendors across the loyalty technology landscape, identifying providers that serve enterprise brands seeking integrated solutions for customer acquisition, engagement, and retention. Snipp's inclusion in the Multisolution Vendor category reflects the breadth of its AI powered platform capabilities, spanning loyalty program management, promotional marketing, receipt-based purchase validation, rebate processing, rewards fulfillment, sweepstakes, and customer intelligence.

"We are proud to be listed in Gartner's 2026 Market Guide for Loyalty Program Vendors," said Atul Sabharwal, Founder and CEO of Snipp. "There is a growing demand by brands for a strong multi-solution technology partner who can connect loyalty, promotions, rewards, and customer intelligence into a unified ecosystem. This inclusion reflects exactly that demand, and we're proud to be acknowledged as a vendor meeting it."

A Unified Platform for a More Complex Customer Engagement Landscape

The Gartner report notes that loyalty programs are evolving beyond traditional retention initiatives and increasingly serve as a mechanism for collecting customer data, enabling personalization, and driving long-term customer value. Mid-to-large brands across CPG, retail, and food and beverage are facing mounting pressure to do more with customer data while managing fragmented technology stacks that keep loyalty, promotions, and purchase insights siloed from one another. Snipp's platform addresses this directly by connecting verified transactional data, first-party data acquisition, and program management within a single ecosystem.

At the core of Snipp's differentiation is its AI-powered receipt processing and purchase validation technology, which enables brands to capture verified purchase behavior at scale, independent of retailer data sharing agreements. Combined with fraud detection and prevention capabilities, rewards management, and configurable loyalty mechanics, the platform gives brands a complete infrastructure for managing customer relationships from initial acquisition through long-term retention.

Inclusion That Reflects Market Direction

Snipp's inclusion in the Gartner 2026 Market Guide validates what the company and its customers have seen in practice: loyalty programs are no longer standalone engagement mechanics. They are becoming strategic customer intelligence platforms, and vendors that can integrate promotions, purchase verification, rewards, and actionable data insights within a single offering are best positioned to deliver measurable business outcomes for the brands they serve.

Snipp serves leading brands across CPG, retail, food and beverage, and other consumer industries globally, supporting loyalty programs, rebate campaigns, promotional activations, and data capture initiatives through a single platform and partner relationship.

Learn More about Snipp loyalty https://www.snipp.com/customer-loyalty-platform

About Snipp

Snipp Interactive Inc. (TSX-V: SPN; OTCPK: SNIPF) is a leading AI-powered technology provider in the global loyalty and promotions sector. Snipp helps brands drive actions, prove performance, and unlock insights across consumer and channel marketing strategies by connecting promotions, sweepstakes, offers, rebates, rewards, loyalty, and media programs directly to verified purchases.

Snipp's modular platform enables Fortune 500 brands, agencies, and partners to run both short-term and always-on programs at scale, transforming engagement into proven outcomes and owned first-party intelligence that powers meaningful, measurable growth. Snipp's AI-powered receipt and transaction validation capabilities have become an industry standard, enabling accurate, retailer-agnostic measurement.

Snipp is headquartered in Vancouver, Canada with a presence across the United States, Canada, Ireland, Europe, and India. Snipp is publicly listed on the TSX Venture Exchange in Canada and is also quoted on the OTC Pink marketplace under the symbol SNIPF. For more information, visit Snipp's website at www.snipp.com and its profile on SEDAR+ at www.sedarplus.ca.

Gartner®, Market Guide for Loyalty Program Vendors, May 2026. Gartner does not endorse any vendor, product or service depicted in its research publications and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

FOR FURTHER INFORMATION PLEASE CONTACT:

Snipp Interactive Inc.
Malcolm Davidson
Chief Financial Officer (Interim)
[email protected]
1-888-99-SNIPP

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties, which may cause actual results to differ materially from the statements made. When used in this document, the words "may", "would", "could", "will", "intend", "plan", "anticipate", "believe", "estimate", "expect" and similar expressions are intended to identify forward-looking statements. Such statements reflect our current views with respect to future events and are subject to such risks and uncertainties. Many factors could cause our actual results to differ materially from the statements made, including those factors discussed in filings made by us with the Canadian securities regulatory authorities. Should one or more of these risks and uncertainties, such as changes in demand for and prices for the products of the company or the materials required to produce those products, labour relations problems, currency and interest rate fluctuations, increased competition and general economic and market factors, occur or should assumptions underlying the forward looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, or expected. We do not intend and do not assume any obligation to update these forward-looking statements, except as required by law. The reader is cautioned not to put undue reliance on such forward-looking statements.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Copyright Snipp Interactive Inc. All rights reserved. All other trademarks and trade names are the property of their respective owners.

SOURCE: Snipp Interactive Inc.

Key Takeaways Ryder trades at a discount forward P/S ratio compared to its industry average, signaling a cheap valuation. Ryder benefits from cost-cutting initiatives and upbeat used vehicle sales. For 2026, Ryder expects adjusted EPS of $14.05 - $14.80 (prior view: $13.45-$14.45). Ryder System, Inc. (R - Free Report)  looks cheap from a valuation standpoint. Considering the forward 12-month price-to-sales ratio (P/S-F12M), Ryder is trading at a discount compared to the industry.

The stock has a forward 12-month P/S-F12M of 0.79X compared with 2.35X for the industry over the past five years. These factors indicate that the stock’s valuation is attractive. Ryder has a Value Score of A.

Ryder P/S Ratio (Forward 12 Months) Vs. Industry Image Source: Zacks Investment Research

Now, the question is whether it is worth buying, holding, or selling the Ryder stock at current prices. Let us delve deeper to find out.

Tailwinds Working in Favor of Ryder StockRyder is being well-served by its focus on contractual growth and operational discipline. Upbeat used vehicle sales, particularly in its fleet management segment, along with stable pricing and improved contractual sales activity, bode well.

Ryder has been making uninterrupted dividend payments for more than 48 years. Ryder’s bottom line has been benefiting from its consistent efforts to reward its shareholders through dividends and share buybacks. During 2022, Ryder paid dividends of $123 million and repurchased shares worth $557 million. In 2023, Ryder paid dividends of $128 million and repurchased shares worth $337 million. In 2024, Ryder returned $456 million in cash to shareholders through share repurchases and dividends. During 2025, Ryder returned $664 million to shareholders through share repurchases and dividend payments. During first-quarter 2026, Ryder returned $272 million to shareholders in the form of share repurchases and dividends.

Such shareholder-friendly moves indicate the company’s commitment to creating value for shareholders and underline its confidence in its business. Dividend-paying stocks provide a solid income stream and have fewer chances of experiencing wild price swings. Dividend stocks, like Ryder, are safe bets for creating wealth, as the payouts generally act as a hedge against economic uncertainty like the current scenario.

Ryder's cost-cutting initiatives in response to the weak freight market conditions are also commendable. Higher free cash flow generation expectation (this reflects lower capital spending due to softer lease sales activity) for the full year is another added positive. Ryder generated $2.59 billion of cash from operating activities in 2025, higher than the $2.26 billion generated in 2024. For 2026, adjusted ROE (return on equity) is expected to be 17-18%. Net cash from operating activities is still projected to be $2.7 billion.

Ryder Stock’s Price PerformanceShares of Ryder have gained 43.5% over the past three months, outperforming the Zacks  Transportation - Equipment and Leasing industry’s 9.7% increase, as well as that of other industry players, The Greenbrier Companies, Inc. (GBX - Free Report) and Wabtec Corporation (WAB - Free Report) .

Ryder Stock’s Three-Month Price Comparison
Image Source: Zacks Investment Research

What Do Earnings Estimates Say for Ryder?The positive sentiment surrounding Ryder stock is evident from the fact that the Zacks Consensus Estimate for the second quarter of 2026 and third quarter of 2026 earnings has been revised upward in the past 60 days. The consensus mark for 2026 and 2027 earnings has also been projected northward in the past 60 days.

The favorable estimate revisions indicate brokers’ confidence in the stock.

Image Source: Zacks Investment Research

Time to Buy Ryder StockApart from being attractively valued, Ryder stock is being well-served by its focus on contractual growth and operational discipline. An increase in used vehicle sales, particularly in its fleet management segment, along with stable pricing and improved contractual sales activity, bodes well. Initiatives to reward its shareholders through dividends and buybacks are praiseworthy as well.

We believe that the positives surrounding the stock (as highlighted throughout the write-up) outweigh the concerns regarding supply-chain disruptions and high fuel costs due to the ongoing conflict in the Middle East, tariff-induced economic uncertainties, risks associated with an economic slowdown, geopolitical tensions and a leveraged balance sheet. We, therefore, suggest investors add Ryder stock to their portfolios for healthy returns. The company’s Zacks Rank #2 (Buy) further supports our thesis. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

- Hybrid generator and flexible power hub that combines hydrogen fuel cells with high performance batteries to deliver an emission-free alternative to diesel generators
- Provides stable AC power whenever and wherever it's needed, with configurable input modules to connect multiple energy assets

LONDON, June 12, 2026 - (JCN Newswire) - Hitachi Energy, a global leader in electrification, has introduced HyFlex(R) Compact - a hybrid generator and flexible power hub that provides zero-emission electricity for temporary and off-grid applications such as construction projects and other infrastructure. The configurable system combines hydrogen fuel cells with high-performance batteries and can integrate additional power sources, delivering stable AC power as a clean alternative to diesel generation.

As electricity demand rises, companies across industry and infrastructure are electrifying operations and cutting emissions, often in locations where grid connections are limited or unavailable. This is increasing demand for flexible power solutions that can perform reliably acrossa wide range of operating conditions, from remote sites to grid-connected environments.

Addressing these requirements calls for power solutions that go beyond single technologies, supported by robust system expertise and integration capabilities. Designed for standalone or grid-connected operation, Hitachi Energy's HyFlex Compact combines hydrogen fuel cells, batteries, power electronics, cooling, and auxiliaries in a single, portable enclosure, all managed by an optimized control system. The system converts hydrogen into clean electricity using fuel cells, producing power, heat, and water with no harmful emissions.

With optional AC and DC input modules, Hyflex Compact can operate as a mobile microgrid, connecting multiple energy assets, providing stable AC power whenever and wherever it is needed. This enables more efficient operation and reduces reliance on hydrogen when additional power sources are available.

"The energy system is being asked to deliver more electricity, with lower emissions and higher resilience, often in places where the grid was never designed for today's demands," said Marco Berardi, Head of Grid & Power Quality Solutions and Service at Hitachi Energy. "HyFlex Compact brings together different technologies through system integration expertise to support a secure electricity supply as energy systems evolve, while helping companies move toward lower emission power."

HyFlex Compact is suitable for applications across a wide range of operating environments, from construction sites and temporary infrastructure such as events and festivals to electric vehicle charging, mining operations, remote industrial sites, critical infrastructure, and hard-to-abate operating environments.

The introduction of the flexible power hub marks an evolutionary step, building on Hitachi Energy's earlier HyFlex developments. Initial pilots explored hydrogen-to-power applications and provided valuable insight into integrating fuel cells, power electronics, and control systems in real-world operating environments1.

Hitachi Energy continues to bring flexible, low-emission solutions to market, underpinned by its expertise in power electronics and system integration. Recent investments in power electronics capabilities, including the inauguration of the Grid & Power Quality Solutions and Service Test Center in Vasteras, Sweden, and the announcement of a new Power Electronics Center of Competence in the United States*1, underscore the company's focus on strengthening the technologies needed to support secure, affordable, sustainable and resilient electricity systems.*1 Hitachi Energy expands its U.S. footprint with $10 million USD investment in North Carolina to meet surging electricity demand

Some of HyFlex pilot projects
1. Hitachi Energy and Air Products pioneer zero-emission construction site in the Netherlands
2. Hitachi Energy's pioneers HyFlex hydrogen-powered generator with shore power system for ships at berth
3. Hitachi Energy enables decarbonization of construction site in Sweden

About Hitachi Energy

Hitachi Energy is a global leader in electrification, powering the electricity era to meet the energy demands of today, and the next 25 years. As the energy arm of Hitachi Group, over three billion people depend on our pioneering, mission critical technologies to power their daily lives. With over a century of innovation, we are addressing the most urgent energy challenge of our time: driving the evolution of the world's energy system to ensure abundant, secure, affordable, and sustainable power for today's generation and the next. With an unparalleled installed base in over 140 countries, we are the grid ecosystem partner across the utility, industry, data center, and transportation sectors. Headquartered in Switzerland, we employ over 56,000 people in 60 countries and generate revenues of around $20 billion USD.
Https://www.hitachienergy.com
https://www.linkedin.com/company/hitachienergy
https://x.com/HitachiEnergy

About Hitachi, Ltd.

Through its Social Innovation Business (SIB) that brings together IT, OT(Operational Technology) and products, Hitachi aims to be a global leader in continuously transforming social infrastructure through digital, contributing to a harmonized society where the environment, wellbeing, and economic growth are in balance. Hitachi operates worldwide across four sectors - Digital Systems & Services, Energy, Mobility, and Connective Industries - as well as a Strategic SIB Business Unit focused on new growth areas. With Lumada at its core, Hitachi creates value by combining data, technology and domain knowledge to solve customer and social challenges. Revenues for FY2025 (ended March 31, 2026) totaled 10,586.7 billion yen, with 606 consolidated subsidiaries and approximately 290,000 employees worldwide. Visit us at www.hitachi.com.

Source: Hitachi, Ltd.

Copyright 2026 JCN Newswire . All rights reserved.

VANCOUVER, BC / ACCESS Newswire / May 27, 2026 / Totec Resources Ltd. ("Totec" or the "Company") (TSXV:TOTC)(OTCQB:TTCRF)(FSE:U0Z0), a leading resource company focused on critical metals and supporting the North American supply chain, is pleased to announce that its common shares have been approved for listing on the OTCQB® Venture Market, operated by OTC Markets Group Inc. The Company's shares are expected to commence trading on the OTCQB on May 28, 2026 under the ticker symbol "TTCRF".

The OTCQB is a U.S. venture stage marketplace for early-stage and developing companies, providing enhanced visibility and access to a broad base of American retail and institutional investors.

Deepak Varshney, Chief Executive Officer of Totec Resources, commented: "Listing on the OTCQB is a meaningful step in our effort to broaden our shareholder base and increase the accessibility of Totec shares for U.S. investors. As we continue to advance our flagship White Willow Lithium-Tantalum-REE Project, we believe this additional market presence will support greater liquidity and strengthen our profile among investors focused on North America's critical minerals supply chain."

U.S. investors will be able to find current financial disclosure and real-time quotes for the Company on www.otcmarkets.com. Totec's common shares will continue to trade on the TSX Venture Exchange under the symbol "TOTC" and on the Frankfurt Stock Exchange under the symbol "U0Z0".

Vertical Amalgamation with its Wholly-Owned Subsidiary

The Company is also pleased to announce that it has completed a vertical short-form amalgamation with its wholly-owned subsidiary, 1540359 B.C. Ltd. (the "Subsidiary"), effective May 6, 2026. The amalgamation was undertaken to simplify the Company's corporate structure by eliminating the Subsidiary as a separate legal entity, thereby reducing ongoing administrative, accounting and compliance costs. The amalgamated company will continue under the name "TOTEC Resources Ltd." and will carry on the same business as was previously conducted through the Company and the Subsidiary. For more information with respect to the foregoing, please refer to the Notice of Change in Corporate Structure on the Company's profile on SEDAR+ at www.sedarplus.ca.

About Totec Resources Ltd.

Totec Resources Ltd. is a North American mineral acquisition and exploration company focused on the development of quality properties that are drill-ready with high-upside and expansion potential. Totec's flagship asset is the White Willow Lithium-Tantalum-REE Project, located approximately 170 kilometres west of Thunder Bay.

For further information, please contact:

Deepak Varshney, CEO and Director
Telephone: 778‐899‐1780 | Email: [email protected]

Cautionary Statement Regarding Forward Looking Information

This press release contains "forward-looking information" and "forward-looking statements" within the meaning of applicable securities legislation. The forward-looking statements herein are made as of the date of this press release only, and the Company does not assume any obligation to update or revise them to reflect new information, estimates or opinions, future events or results or otherwise, except as required by applicable law. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budgets", "scheduled", "estimates", "forecasts", "predicts", "projects", "intends", "targets", "aims", "anticipates" or "believes" or variations (including negative variations) of such words and phrases or may be identified by statements to the effect that certain actions "may", "could", "should", "would", "might" or "will" be taken, occur or be achieved.

In making the forward-looking statements included in this news release, the Company has applied several material assumptions, including that the Company's financial condition and development plans do not change as a result of unforeseen events. Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of the Company to control or predict, that may cause the Company's actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out herein.

There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information, or financial outlook incorporated by reference herein, except in accordance with applicable securities laws.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: Totec Resources Ltd.

Key Takeaways Ryder System earned the 2026 VETS Index's 3 Star Employer status for veteran hiring efforts. R has hired nearly 18,000 veterans since 2011, supporting workforce stability and execution. Ryder System boosted capital returns to $664M in 2025, including buybacks and dividends. Ryder System (R - Free Report) is benefiting from employee-friendly initiatives that are boosting the company’s operational efficiency. The company’s commitment to shareholders is encouraging and bodes well for its prospects. Due to these tailwinds, R shares have performed impressively on the bourse. If you have not taken advantage of its share price appreciation yet, it’s time to do so.

Let’s delve deeper.

Factors Favoring R StockNorthward Earnings Estimate Revision: The Zacks Consensus Estimate for earnings per share (EPS) has been revised upward by 3.7% over the past 60 days for the current year. For 2027, the consensus mark for EPS has moved 5.3% north over the same time frame. The favorable estimate revisions indicate brokers’ confidence in the stock.

Robust Price Performance: A look at the company’s price trend reveals that its shares have gained 65.5% over the past year, surpassing the  Zacks Transportation - Equipment and Leasing industry’s 17.4% growth.

Image Source: Zacks Investment Research

Positive Earnings Surprise History: Ryder System has an encouraging earnings surprise history. The company's earnings outpaced the Zacks Consensus Estimate in three of the trailing four quarters and missed once in the remaining, delivering an average surprise of 4.01%.

Solid Zacks Rank: R currently carries a Zacks Rank #2 (Buy).

Growth Factors: Ryder System continues to strengthen its workforce strategy through veteran-focused hiring and retention initiatives, earning recognition as a 2026 VETS Index 3 Star Employer. The company’s efforts are reinforced by long-standing programs such as Hiring Our Heroes, through which Ryder System has hired nearly 18,000 veterans since 2011. It also provides transition support initiatives like the Veteran Buddy Program and the Pathway Home diesel technician training program. These initiatives not only expand Ryder’s skilled labor pipeline but also enhance workforce stability and operational execution by leveraging veterans’ technical expertise, discipline and leadership capabilities.

Moreover, R’s focus on returning capital to shareholders through dividends and buybacks aligns with its strategy of maintaining a balanced and sustainable growth model. Ryder System returned $456 million in cash to shareholders in 2024 and increased total capital returns to $664 million in 2025, including $519 million in share repurchases and $145 million in cash dividends. The company increased cash dividend payments consistently from $128 million in 2023 to $135 million in 2024 and $145 million in 2025, reflecting strong cash generation and continued emphasis on shareholder returns.

Other Stocks to ConsiderInvestors interested in the Zacks Transportation sector may consider Expeditors International of Washington, Inc. (EXPD - Free Report) and International Seaways (INSW - Free Report) . 

EXPD currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Expeditors has an expected earnings growth rate of 11.9% for the current year.  The company has an encouraging earnings surprise history. Its earnings outpaced the Zacks Consensus Estimate in each of the trailing four quarters, delivering an average beat of 13.96%.

INSW currently sports a Zacks Rank #1.

INSW has an expected earnings growth rate of more than 100% for the current year. The company has an encouraging earnings surprise history. Its earnings topped the Zacks Consensus Estimate in each of the trailing four quarters, delivering an average beat of 33.93%.

Third quarter sales reflect the impact of the continued changes in the global geopolitical landscape that has temporarily impacted outbound shipments from the USA to the Middle East distribution partners

Third quarter sales and year-to-date sales growth of Dream Water® Canada E-commerce of 16% and 13% respectively offset by a decline in Dream Water® Canada Retail of 15% and 6% respectively compared to same periods last year

Third quarter sales and year-to-date sales growth of LivRelief™ E-commerce of 60% and 32% respectively offset by a decline in LivRelief™ Retail of 30% and 27% respectively compared to same periods last year

Vancouver, British Columbia--(Newsfile Corp. - May 29, 2026) - Delivra Health Brands Inc. (TSXV: DHB) (OTCQB: DHBUF) ("Delivra Health" or the "Company"), a consumer packaged goods company uniquely positioned in the health and wellness sector, is pleased to announce its financial and operating results for the three and nine months ended March 31, 2026. The Delivra Health portfolio features innovative brands Dream Water® and LivRelief™, which deliver relief from common health issues such as sleeplessness, chronic pain and anxiety.

The Company's quarterly and year-to-date revenue has been mainly impacted by a reduction in its sales from the USA to its distribution partners in the Middle East. The global geopolitical conflict in the Middle East, including the closure of the Strait of Hormuz, impacted the flow and sales of the Company's Dream Water® product to its distributors and partners, and accounts approximately for the quarterly and year-to-date differences in sales compared to the prior year.

In addition to the impact on sales, some of the Company's product ingredients simultaneously experienced a price increase. The Company anticipates shipping and delivery to this region to resume in the fourth quarter and fiscal 2027, with new order commitments and growth plans from its international partners to restore sales to prior levels to this geopolitical conflict. As a continuation from the prior quarter, the Company continues to see encouraging momentum in its targeted e-commerce strategy and continued growth within the Dream Water® brand. Year-to-date e-commerce sales increased 13% for Dream Water® Canada and 32% for LivRelief™, reflecting strong consumer engagement and repeat purchasing behavior in the overall North American business.

The Company has also completed the transition of its licensed LivRelief™ Infused product line-up which will also enhance a revised distribution channel. While these factors have created near-term variability in reported results, underlying consumer demand for the Company's core brands remains solid and is proven in the increase in demand across e-commerce channels. Management of Delivra Health is actively addressing fluctuations in distribution timing and engaging in channel optimization to stabilize and accelerate growth in fiscal 2027.

Management Commentary

"Management continues to monitor the developments of the global conflicts, particularly in the Middle East and is in constant communication with its local partners, planning for sales activity and its innovation pipeline for fiscal 2027 and beyond. Our results this quarter reflect the adverse impact of geopolitical developments on sales, and increase in costs of logistics and input material due to the impact of tariffs on our vendors. At the same time, we are encouraged by the strength of our core business fundamentals, and our e-commerce strategy continues to evolve and grow, and the Company continues to invest in this growing channel," said Gord Davey, President and Chief Executive Officer of Delivra Health Brands Inc. "In the next quarter and 2027 fiscal year, the Company will continue to advance its innovation projects, stabilize its LivRelief™ Infused business, stabilize retail ordering patterns and continue to grow its e-commerce business levels to restore prior quarterly sales levels."

Financial Highlights for the Nine Months Ended March 31, 2026
(Expressed in thousands of Canadian dollars, except share and per share amounts)

Net revenue: In the nine months ended March 31, 2026, the Company reported total net revenue from continued operations of $6,887 compared to $9,012 in same period last year. The $2,125 or 24% decrease in net revenue was mainly due to: (i) the decrease in sales of Dream Water® in the United States of $1,785 as a result of the conflict in the Middle East and a decrease in Dream Water® sales in Canada by $5 and (ii) reduced LivRelief™ OTC sales by $54 and lower activity of LivRelief™ Infused licensed products by $281 due to the transition to a new licensed distribution partner.

Gross profit and gross profit margin: In the nine months ended March 31, 2026, the Company reported year-to-date gross profit of $2,784 and a gross profit margin of 40% as compared to $4,444 and 49% in same period last year. The decrease in gross profit is driven by lower revenue and higher product cost due to price increases by certain vendors and the reduction in gross profit margin was the result of a different product and customer mix in this quarter compared to same quarter last year.

Expenses including SG&A and excluding non-cash items: In the nine months ended March 31, 2026, the Company reported expenses of $4,099 compared to $4,585 in the same period last year, representing an 11% reduction. General and administrative costs were higher year-to-date fiscal 2026 compared with same period last year by $42 or 1% mainly as a result of higher investor relation programs and higher professional and consulting services which were partially offset by lower salaries costs. Prior year fiscal 2025, year-to-date sales and marketing expenses were higher than the same period of fiscal 2026 sales and marketing expenses by $528 or 32% given that the Company released in November 2024 two major marketing campaigns, 'Shush Your Mind' for Dream Water® and 'Quiets Chronic Pain' for LivRelief™.

Adjusted EBITDA(1): For the nine months ended March 31, 2026, the Company reported Adjusted EBITDA of $(1,262) compared to $(51) in the same period last year. This reduction in Adjusted EBITDA was mainly driven by lower sales volume and lower gross profit as discussed above.

Financial Highlights for the Three Months Ended March 31, 2026
(Expressed in thousands of Canadian dollars, except share and per share amounts)

Net revenue: In the three months ended March 31, 2026, the Company reported total net revenue of $1,247 as compared to $3,095 in same period last year. The $1,848 or approximately 60% decrease is attributed to: (i) a $1,803 decline in Dream Water® sales in USA due to a reduction in outgoing shipments to the Middle East as a result of the geopolitical conflict and a $17 reduction in Dream Water® sales in Canada (ii) a $39 reduction in licensed LivRelief™ Infused sales activity, offset by an in increase in LivRelief™ sales by $11 or 5% and this increase was driven by an increase in e-commerce sales by 60%, offset by a decrease in retail sales by 30%.

Gross profit and gross profit margin: In the three months ended March 31, 2026, the Company reported gross profit of $311 and a gross profit margin of 25% compared to $1,552 and 50% in same period last year. The decrease in gross profit is mainly driven by lower revenue and higher product cost and the reduction in gross profit margin is mainly driven by changes in customer and product mix in this quarter compared to same quarter last year.

Expenses including SG&A and excluding non-cash items: In the three months ended March 31, 2026, the Company reported expenses of $1,261 as compared to $1,437 in the same period last year, representing a 12% decrease. The decrease was mainly driven by lower investments in marketing campaigns and digital marketing programs of $103 or 25% and a reduction in general and administrative costs of $73 or 7% mainly driven by lower costs of insurance, investor relations, and salaries, bonus and benefits expenses partially offset by increased professional and consulting services.

Adjusted EBITDA(1): In the three months ended March 31, 2026, the Company reported Adjusted EBITDA of $(949) as compared to $124 in the same period last year. This reduction in Adjusted EBITDA was mainly driven by lower sales volume and lower gross profit as discussed above.

Summary of Key Financial Results

For the three months ended
March 31

For the nine months ended
March 31
($000's, except share and per share amounts)
2026

2025

2026

2025
Continued operations:
$

$

$

$
Net revenue
1,247

3,095

6,887

9,012
Cost of sales
935

1,534

4,050

4,478
Inventory write-down
1

9

53

90
Gross profit
311

1,552

2,784

4,444
Expenses excluding non-cash expenses
1,261

1,437

4,099

4,585
Depreciation and amortization and share based compensation
28

397

135

1,192
Total Expenses
1,289

1,834

4,234

5,777
Loss from Operations
(978)
(282)
(1,450)
(1,333)Other (expense) income
(50)
(140)
(80)
(376)Net gain (loss) from continued operations
(1,028)
(422)
(1,530)
(1,709)Net gain (loss) per share - basic
(0.03)
(0.01)
(0.05)
(0.06)Adjusted EBITDA(1) (non-IFRS measure)

For the three months ended
March 31

For the nine months ended
March 31
($000's, except share and per share amounts)
2026

2025

2026

2025
Loss from operations
(978)
(282)
(1,450)
(1,333)Inventory write-down
1

9

53

90
Depreciation and amortization
-

326

27

978
Share-based compensation
28

71

108

214
Adjusted EBITDA(1)
(949)
124

(1,262)
(51)Expenses excluding non-cash items

For the three months ended
March 31

For the nine months ended
March 31
($000's, except share and per share amounts)
2026

2025

2026

2025
General and administration
954

1,027

2,980

2,938
Sales and marketing
307

410

1,119

1,647
Total
1,261

1,437

4,099

4,585
Notes:

"Adjusted EBITDA" is defined as loss from operations before interest, taxes, depreciation and amortization and adjusted for share-based compensation, common shares issued for services, fair value effects of accounting for biological assets and inventories, asset impairment and write-downs, discontinued operations and other non-cash items. This is a non-IFRS reporting measure. For a reconciliation of this measure to the nearest IFRS measure, see "Adjusted EBITDA (non-IFRS measure)" and "Non-IFRS Measures" in the Q3 2026 MD&A. About Delivra Health Brands Inc.

Helping people take control of their health with alternative wellness solutions is what energizes the Delivra Health team! The Delivra Health portfolio features innovative brands like Dream Water® and LivRelief™, which deliver relief from common everyday issues like chronic pain, anxiety, and sleeplessness. Delivra Health products have allowed millions of customers to reclaim their mobility, energy, and in turn, quality of life. The websites of the Company's two subsidiaries are Dream Water® and LivRelief™. For more information, please visit www.delivrahealthbrands.com.

Non-IFRS Measures, Reconciliation and Discussion

This press release contains references to "Adjusted EBITDA" which is a non-International Financial Reporting Standards ("IFRS") financial measure. Adjusted EBITDA is a measure of the Company's profit/loss from operations before interest, taxes, depreciation, and amortization and adjusted for share-based compensation, common shares issued for services, fair value effects of accounting for biological assets and inventories, asset impairment and write-downs, discontinued operations and other non-cash items, and is a non-IFRS measure.

This measure can be used to analyze and compare profitability among companies and industries, as it eliminates the effects of financing and capital expenditures. It is often used in valuation ratios and can be compared to enterprise value and revenue. This measure does not have any standardized meaning according to IFRS and, therefore, may not be comparable to similar measures presented by other companies.

There are no comparable IFRS financial measures presented in Delivra Health's financial statements. Reconciliations of the supplemental non-IFRS measure are presented in the Company's management discussion and analysis for the three and nine months ended March 31, 2026 (the "Q3 2026 MD&A"). This non-IFRS financial measure is presented because management has evaluated the financial results both including and excluding the adjusted items and believes that the non-IFRS financial measure presented provides additional perspective and insights when analyzing the core operating performance of the business. The Company believes that the supplemental measure provides information which is useful to shareholders and investors in understanding the Company's performance and may assist in the evaluation of the Company's business relative to that of its peers.

The non-IFRS financial measure should not be considered superior to, as a substitute for, or as an alternative to, and should be considered in conjunction with the IFRS financial measures presented in the Company's financial statements. For more information, please see "Adjusted EBITDA (non-IFRS measure)" and "Non-IFRS Measures" in the Q3 2026 MD&A, which is available under the Company's SEDAR+ profile on www.sedarplus.ca.

Cautionary Note Regarding Forward-Looking Statements
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates, and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements include, among other things, statements with respect to the Company's products offering relief from chronic pain, anxiety, and sleeplessness; new order commitments and growth plans from the Company's international partners; restoration of sales; growth within the Dream Water brand; increased demand and growth across e-commerce channels; purchasing behavior for the Company's products; advances in the Company's innovation projects; stabilization of the LivRelief™ Infused business and retail ordering patterns; expectations regarding positive financial results in the future; and statements regarding the Company's growth objectives.

These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the cannabis markets where the Company operates; changing consumer habits; the ability of the Company to successfully achieve its business objectives; plans for expansion; political and social uncertainties; inability to obtain adequate insurance to cover risks and hazards; employee relations and the presence of laws and regulations that may impose restrictions on cultivation, production, distribution, and sale of cannabis and cannabis-related products in the markets where the Company operates. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

Additional information regarding this and other risks and uncertainties relating to the Company's business are contained under the heading "Risk Factors" in the Company's annual information form dated March 2, 2021, and under the heading "Risks and Uncertainties" in the Q3 2026 MD&A filed under the Company's profile on SEDAR+ at www.sedarplus.ca.

Neither the TSX-V nor its Regulation Services Provider (as that term is defined in the policies of the TSX-V) accept responsibility for the adequacy or accuracy of this release.

Investor Relations:
Jack Tasse
Chief Financial Officer
[email protected]
1-877-915-7934

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/299508

Source: Delivra Health Brands Inc.

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

FORT LAUDERDALE, FL / ACCESS Newswire / June 1, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, is pleased to announce the approval of its generic Rivaroxaban tablets of 2.5mg, 10mg, 15mg and 20mg for the Canadian market. Rivaroxaban is the generic equivalent of the brand name anticoagulant, Xarelto®.

Rivaroxaban is a direct oral anticoagulant prescribed to treat and prevent deep vein thrombosis and pulmonary embolism. It is also widely utilized to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.

The global market for Rivaroxaban is estimated to reach $12.7 Billion in 2026 and is set to expand to approximately $30.5 Billion by 2035, growing at a CAGR of 10.19% during the forecast from 2026 to 2035, (Business Research Insights). According to IQVIA Pharmafocus 2028, the Canadian pharmaceutical market accounts for approximately 2.1% of the global pharmaceutical market and ranks as the 6th largest worldwide.

Sunshine Biopharma has established a robust distribution network across Canada through its wholly owned Canadian subsidiary, Nora Pharma Inc. The addition of Rivaroxaban to our portfolio of drugs represents a strategic expansion for the Company in the area of anticoagulants. The Company's first generic anticoagulant, Apixaban (brand name Eliquis®) has been on the market for over three years. It is anticipated that Sunshine Biopharma's Rivaroxaban will be ready to ship to pharmacies in October 2026.

"We are pleased to introduce Rivaroxaban oral tablets as the newest addition to our expanding portfolio of high-quality generic drugs," said Dr. Steve Slilaty, CEO of Sunshine Biopharma. "This approval strengthens our position in the generics market and reflects our ongoing commitment to delivering affordable medicines that patients and healthcare providers can rely on."

About Sunshine Biopharma Inc.

Sunshine Biopharma currently has 60 generic prescription drugs on the market in Canada and approximately 12 additional drugs scheduled to be launched in the remainder of 2026. In addition, Sunshine Biopharma is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and (ii) PLpro protease inhibitor, a small molecule for treatment of SARS Coronavirus infections. For more information, please visit: www.sunshinebiopharma.com.

All registered trademarks are the property of their respective owners.

Safe Harbor Forward-Looking Statements

This press release contains forward-looking statements which are based on current expectations, forecasts, and assumptions of Sunshine Biopharma Inc. (the "Company") that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected. These statements appear in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, including statements related to the Company's drug development activities, financial performance, and future growth. These risks and uncertainties are further described in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in the Company's filings with the SEC. Reference is hereby made to cautionary statements and risk factors set forth in the Company's most recent SEC filings.

For more information, please contact:

Camille Sebaaly, CFO
Direct Line: 514-814-0464
[email protected]

SOURCE: Sunshine Biopharma Inc.